CMS projects that the average Medicare Advantage monthly premium will fall 16.5 percent in 2027, from $14.37 to $12.00. Most Medicare beneficiaries will continue to have access to a large number of competing plans.
Those numbers offer a useful look at the economics of managed care.
Provider networks, negotiated rates, care management, data, and competition all shape the final product a beneficiary sees during open enrollment.
Understanding those mechanisms is useful well beyond Medicare.
What is changing for Medicare Advantage in 2027?
According to the Centers for Medicare & Medicaid Services, the weighted average monthly Medicare Advantage premium is projected to fall from $14.37 in 2026 to $12.00 in 2027.
CMS also reports that more than 99 percent of Medicare beneficiaries will have access to at least one Medicare Advantage plan and 97 percent will have 10 or more options.
Plan availability is contracting somewhat.
KFF analysts found that the average Medicare beneficiary will have 28 Medicare Advantage plans with prescription drug coverage available in 2027, down from 32 in 2026.
Twenty-eight choices still represent a substantial market.
For beneficiaries, the details inside those choices matter more than the headline number alone. Premiums, provider networks, drug coverage, prior authorization rules, out-of-pocket limits, and supplemental benefits can all vary.
Competition happens across the entire package.
How does managed care create opportunities to lower costs?
Medicare Advantage plans receive federal payments to provide covered care to their members.
That structure gives plans a reason to manage total spending across a population.
A plan can negotiate reimbursement rates with hospitals and physicians. It can create a network around providers willing to meet particular terms. It can invest in programs for chronic disease, preventive care, and medication management. It can examine utilization patterns and identify areas where patients are receiving care in unusually expensive settings.
Each of those activities changes the economics of the plan.
A company serving millions of members can negotiate across a large patient base. It can operate technology infrastructure across many markets. It can build clinical analytics once and use them across a national population.
Those capabilities become increasingly valuable at scale.
Provider networks are one of the main ways plans use purchasing power
Health insurance networks often become visible to consumers when something goes wrong.
A doctor leaves a plan. A hospital is no longer covered. A beneficiary discovers that a preferred specialist is out of network.
Those disruptions deserve attention because access is a core measure of whether a health plan works.
Networks also perform an economic function.
A health plan can offer providers access to a large group of patients in exchange for agreed reimbursement rates and contractual standards. That negotiation can put pressure on health care prices.
The size of the patient population affects the strength of the negotiation.
A national insurer representing millions of covered lives can bring substantial volume to a hospital system or physician group. That purchasing power can produce lower contracted rates or other terms that influence total spending.
A useful regulatory framework measures both sides of the equation: whether the network contributes to affordability and whether beneficiaries can still reach appropriate care.
Competition gives Medicare Advantage plans a reason to improve the offer
Every fall, Medicare Advantage organizations compete for beneficiaries.
A plan with an unattractive premium, weak provider network, poor drug coverage, or cumbersome member experience can lose enrollment to another option.
Consumer choice therefore creates a form of market discipline.
Health insurance remains complicated, and comparing dozens of plans can be difficult. Beneficiaries may care more about keeping a specific physician or medication covered than saving a few dollars on a premium.
Clear information becomes essential in a market with this many variables.
Competition still creates pressure.
Plans have a reason to negotiate harder, use infrastructure more efficiently, and design benefits people will choose.
The projected decline in average premiums gives us one visible measure of that competitive environment.
Medicare Advantage also has a taxpayer-cost problem policymakers should address
A serious assessment of Medicare Advantage has to include what the federal government pays.
The Medicare Payment Advisory Commission's March 2026 report to Congress estimates that Medicare will pay Medicare Advantage plans about $76 billion more in 2026 than the program would spend for similar beneficiaries in traditional fee-for-service Medicare.
MedPAC attributes much of that difference to favorable selection and differences in diagnostic coding.
That is a large cost and an important policy problem.
Medicare Advantage plans also have useful capabilities: negotiated networks, population-level data, care coordination, pharmacy management, and consumer competition.
Payment rules determine whether taxpayers receive enough value from those capabilities.
Better risk adjustment and stronger payment accuracy can put greater pressure on plans to compete through real operational efficiency.
The standard should be demanding.
Can the plan coordinate care more effectively?
Can it negotiate better terms?
Can it prevent avoidable medical spending?
Can it offer a product beneficiaries value?
Can it do those things at a price that makes sense for the taxpayer?
Scale makes expensive health infrastructure viable
The largest Medicare Advantage organizations operate claims systems, fraud detection, customer-service operations, provider contracting teams, clinical analytics, pharmacy networks, and digital member tools.
Those systems require large upfront and ongoing investments.
A national organization can spread the cost across millions of members.
It can also learn across those millions of members.
Claims data can show which interventions are associated with fewer hospital admissions. Care-management systems can identify people who appear at elevated risk. Pharmacy data can flag adherence problems. Provider data can reveal substantial differences in cost and utilization.
Scale creates the capacity to build those systems.
Good incentives determine how productively that capacity is used.
What should beneficiaries and policymakers look at in 2027?
Premiums are one measure.
Access matters too.
So do quality, out-of-pocket costs, drug coverage, administrative burden, and taxpayer value.
For a beneficiary comparing plans this fall, the useful questions are practical:
Is my doctor in the network?
Are my prescriptions covered?
What could I pay if I get sick?
What services require prior authorization?
How large is the provider network where I live?
For policymakers, the questions expand:
Are federal payments accurate?
Are plans competing based on real efficiency?
Can beneficiaries compare options clearly?
Are network rules protecting access?
Are plans generating measurable health value for the money Medicare spends?
These are outcome questions.
They give policymakers a better basis for evaluating Medicare Advantage than corporate size alone.
The bottom line
A 16.5 percent projected decline in average premiums during a period of broader medical-cost pressure is worth understanding.
Managed care gives large health plans tools that can influence costs: purchasing power, provider networks, population data, coordinated benefits, and substantial technology infrastructure.
Medicare Advantage also carries substantial taxpayer costs that require reform.
Both belong in a serious assessment of the program.
The value of scale depends on what a company does with it. Medicare policy should reward the plans that turn scale into lower costs, better access, and better care.